Taking Matters Into Your Own Hands

by | Mar 9, 2015 | 0 comments

Do you have a rare form of CMT?

We were contacted recently from a patient with CMT2D who was looking for advice on how to make a difference. Our recommendations for all people with an ultra-rare form of CMT who want to get involved:

1) Join the global registries for inherited neuropathies (GRIN).

2) Join the Inspire Community at: Charcot-Marie-Tooth (CMT) Support Community – Inspire.

3) Create a Facebook page specifically for CMT2D or your form of CMT and encourage all patients that find you to join the GRIN.

4) Go and do a search on CMT2D or your form of CMT and to learn where your form of CMT is being worked on. Reach out to the authors of research papers (an email address should be included at the bottom of the abstract).

5) Email every scientist in the world working on your form of CMT and ask if they need a skin biopsy from patients to advance research. Hopefully, your local university has success in growing out skin fibroblast cell lines following punch biopsies. They would grow out a large number of skin fibroblast cells that they would freeze into 10 separate vials. You could then have a vial shipped to 10 different labs studying your form of CMT. They would ship overnight, on dry ice. HNF can help with this process if cells are needed by researchers.

Initially, the most important thing is to find other patients with your form of CMT and ask if they too will have skin biopsies performed. If you are able to fundraise, you can earmark the funds for your type of CMT, through the Hereditary Neuropathy Foundation. We can help identify what the status of the field is for your form of CMT, and help prioritize research initiatives that need funding.

With over 80 different CMT causal genes now identified, patients must become active and helping to drive research. Except for CMT1A, CMT2A and CMTX, all other forms are considered ultra-rare, meaning less than 600 Americans are impacted.

Rare forms of CMT must unite in order to help fund, and drive research, to advance to the point where a pharmaceutical company may be interested in further investing in an ultra-rare CMT. Seed funding is needed for basic research until a discovery is made that peeks the interest of industry. TOGETHER, we will make a difference for ALL forms of CMT!

Learn more on this topic

Related Blog Posts

Double Your Donation

Corporate matching gift programs are charitable giving programs setup by corporations in which the company matches donations made by employees to eligible nonprofit organizations. For example, if a donor works for Bank of America and donates $100 to the Hereditary Neuropathy Foundation, Bank of America will double the donation by also writing a check for $100.

Now GRIN is Accessible in 141 Different Languages!

Now GRIN is Accessible in 141 Different Languages!

The Global Registry for Inherited Neuropathies (GRIN) has implemented Google Translate. Why did we choose Google? Because Google is leading the way in teaching computers how to interpret meaning, avoiding the traditional method of decoding language.

Accelerating Patient Access to Investigational Drugs in 2015

Accelerating Patient Access to Investigational Drugs in 2015

Currently the FDA is working to update the process for physicians applying for accelerated patient access to investigational drugs, while the drug or biological product is being tested in clinical trials. This will also be important for the CMT community as clinical trials for this disease are being launched.

Do You Have Charcot-Marie-Tooth Type 4 (CMT4)? – We Need Your Help

Autosomal recessive demyelinating CMT4 patients present with earlyonset and slowly progressing symptoms. These include progressive distally accentuated weakness and atrophy of muscles in the lower limbs. In addition, patients may have weakness and atrophy of hands, sensory loss and pes cavus (high-arched feet), and walking difficulties. Further information on CMT4 can be found at Orphanet.

Hot Off the Press – Potential Treatment for CMT1A

Two recent publications from Pharnext describe a novel synergistic combination of 3 drugs (baclofen, naltrexone and sorbitol) and its effect on CMT1A both in the lab and in a phase II clinical trial. These 3 drugs already approved but for unrelated conditions, are combined at new optimal lower doses and under a new formulation. This novel potential therapeutic is called PXT-3003.

Support CMT Therapeutic Alliance

HNF has entered into a joint venture – the CMT Therapeutic Alliance – with a unique non profit organization (BioPontis Alliance for Rare Diseases) that brings professional drug discovery capabilities to translate our research results into potential treatments.

Scientific Advisory Board Meeting

Scientific Advisory Board Meeting

On the 7th of November we convened our scientific advisory board meeting at the HNF offices in NY. We have written a detailed review that has been published and captures all of the discussion and make this freely available to the scientific community.

Join the conversation

Leave a Comment


Submit a Comment

Your email address will not be published. Required fields are marked *


Join for notifications on events, campaigns, & news